Neurology

Duchenne muscular dystrophy Histopathology
Biotech

Audentes Therapeutics to develop gene therapies for two types of muscular dystrophy, including Duchenne

By Matthew Herper

Jaenisch-Liu
In the Lab

In STAT Madness, CRISPR tools to treat brain disorders capture Editors’ Pick

By Sharon Begley

Teen Juul
Health

FDA is investigating reports of seizures after vaping

By Megan Thielking

Health

When the ‘real thing’ becomes a mirage: How patients in Alzheimer’s trials are coping with the treatment’s failure

By Andrew Joseph

Dentate gyrus neurons
In the Lab

Old brains still make neurons, study finds, offering a possible way to protect against Alzheimer’s

By Sharon Begley

In the Lab

By decoding flickering brain signals, scientists envision a new way to detect consciousness

By Eric Boodman

Blood plasma sample
In the Lab

In a field full of failures, a new blood test to predict Alzheimer’s aims to give drug makers a needed tool

By Sharon Begley

Pharmalot

Pharmalittle: Roche halts Alzheimer’s drug trials; is public health jeopardized as FDA fast tracks generics?

By Ed Silverman

Sanofi Genzyme Boston
Biotech

Sanofi-Genzyme inappropriately sought confidential patient information, suit alleges

By Kate Sheridan

Glioblastoma Cells
In the Lab

In small studies, cancer vaccines generate immune responses against brain tumors

By Andrew Joseph

Dementia
In the Lab

Tests used to determine if someone needs dementia evals are riddled with bias, study finds

By Eric Boodman

Exhaust pipe
Health

Exposure to air pollution during pregnancy or early life linked to autism diagnosis

By Karen Weintraub

Brain neurons
Biotech

A pharma veteran best known for biotech reflects on leading a startup, pricing a drug, and investing in politics

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Pill stomach
Biotech

Sick of a daily pill? A Boston biotech wants to make a daily Alzheimer’s drug last for a week — and they’re working on more

By Kate Sheridan

STAT Brain Signals Final GIF
In the Lab

With brain implants, scientists hope to translate paralyzed patients’ thoughts into speech

By Sharon Begley

Alzheimers Association
In the Lab

New prize offers $2 million for finding key to Alzheimer’s in past research

By Sharon Begley

Appendix - Parkinson’s disease
In the Lab

It started as a ‘weird idea,’ but a new study shows the appendix can initiate Parkinson’s

By Sharon Begley

Robert Moir
In the Lab

How an outsider in Alzheimer’s research bucked the prevailing theory — and clawed for validation

By Sharon Begley

Epilepsy Student llustration
First Opinion

Epilepsy, my life-threatening condition, is not your ‘undue burden’

By Kurt Eichenwald

Biotech

Pfizer, Bain launch a startup to focus on nervous system diseases

By Jonathan Saltzman — Boston Globe

Homeopathy vials
Health

Crowdfunding raises millions for unproven — and potentially harmful — treatments

By Megan Thielking

Brain map
Biotech

New chemical eyed in fight vs. Alzheimer’s

By Jonathan Saltzman — Boston Globe

Biotech

New data for Genentech’s MS drug shows benefit of early treatment

By Kate Sheridan

Single white lab mouse
In the Lab

Can building a better research mouse open the black box of Alzheimer’s?

By Kate Sheridan

Ear Hair Cells
In the Lab

After decades of false starts, Harvard team says it’s found the ‘missing link’ in how we hear

By Eric Boodman

ACT UP 1989
Health

As Alzheimer’s drug developers give up on today’s patients, where is the outrage?

By Sharon Begley

Empty pipeline
Pharma

That pathetic Alzheimer’s pipeline? It’s even worse than you think

By Sharon Begley

Special Report

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

By Eric Boodman

In the Lab

Drugs aimed at a sliver of Parkinson’s patients may benefit many more than thought — and boost a biotech

By Sharon Begley

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy